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This review provides perspectives on the utility of magnetic resonance imaging (MRI) as a neuroimaging approach
in the development of novel treatments for Alzheimer’s disease. These considerations were generated in a
roundtable at a recent Wellcome Trust meeting that included experts from academia and industry. It was agreed
that MRI, either structural or functional, could be used as a diagnostic, for assessing worsening of disease status, for
monitoring vascular pathology, and for stratifying clinical trial populations. It was agreed also that MRI
implementation is in its infancy, requiring more evidence of association with the disease states, test-retest data,
better standardization across multiple clinical sites, and application in multimodal approaches which include other
imaging technologies, such as positron emission tomography, electroencephalography, and
magnetoencephalography.Introduction
This article is the result of a roundtable held at the
Wellcome Trust in the context of the meeting ‘Biomarkers
for Brain Disorders: Challenges and Opportunities’ in
February 2013. The focus was on the relevance of neuro-
imaging biomarkers in the development of novel treat-
ment in Alzheimer’s disease (AD), with a particular focus
on magnetic resonance imaging (MRI). AD is the most
common form of senile dementia associated with cognitive
decline, regional brain hypometabolism/atrophia, β-amyloid
plaque deposition, accumulation of phosphorylated tau-
containing neurofilament tangles (NFTs), vascular path-
ology, and neuroinflammation, and the diagnostic criteria
of AD were recently amended [1]. Based on the experi-
ence of current precompetitive consortia such as the
Alzheimer Disease Neuroimaging Initiative (ADNI) [2],
the Innovative Medicine Initiative Pharma-Cog [3], or the
Dominant Inherited Alzheimer Network [4], the general
consensus was that MRI has great potential for improving
novel drug development but is not a mature biomarker
yet. As for other biomarkers, the current applications of
neuroimaging include assistance in (a) the diagnosis of* Correspondence: andreasjeromin@gmail.com
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2014dementia, (b) the selection of subjects for enrollment in
clinical trials or for stratification, (c) the tracking of
disease progression, (d) providing evidence for target
engagement for new therapeutic agents, and (e) providing
evidence of disease-modifying effects (that is, normalization
of a pathologic signal in association with clinical improve-
ment (surrogate marker)). The MRI literature is partially
supportive for the first three applications, whereas the
database for the last two applications is still growing [5-7].
The present article should not be seen as an exhaustive re-
view of neuroimaging in AD research (as shown in [8-10])
but as an introduction to the uneven status of advance-
ment of MRI technology for drug development.A practical question
Developing a new drug is an evidence-based exercise.
Collecting evidence relevant for decision-making to sup-
port the development of a novel chemical entity (NCE) re-
quires investment in methodologies that are reliable, valid,
and clinically relevant. In other words, we should answer
the question: is it worthwhile to include a neuroimaging
assessment in a clinical trial for a novel treatment in AD?
If the method has regulatory approval, the inclusion in a
clinical trial is generally supported. If not, the quality of
the scientific data, the simplicity in execution, thetral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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cost would drive the decision for including imaging end-
points. In this case, expectations about trial outcome
should be adjusted since the imaging measurements may
deliver exploratory data whose real value will be appreci-
ated only when combined with data coming from other
research groups, possibly organized within precompetitive
consortia (for example, ADNI). Remarkably, only a limited
number of imaging biomarkers are endorsed by regulatory
agencies (Table 1). A series of methodological challenges
are still facing the neuroimaging scientific community.
The most important are (a) the interpretation of the
biological meaning of the various neuroimaging measure-
ments and their relationship with disease severity, (b) the
test-retest reliability, and (c) the proper implementation
into multi-center clinical trials. Hence, one of the main
goals of the scientific community should be to provide
answers to these questions and contribute to the regula-
tory approval of the neuroimaging methods.
Neuroimaging in Alzheimer’s disease: the legacy
of positron emission tomography
Different neuroimaging modalities are at different stages
of maturity regarding implementation in AD research.
For example, for more than two decades, molecular neu-
roimaging assessed with positron emission tomography
(PET), aimed to investigate key neurochemical processes
at work in AD, has been used with a certain success
to assist the diagnostic process in AD research [9,10].
PET with [35]-18Fluoro-2-deoxy-D-glucose (FDG) used
to map the cerebral metabolic rate of glucose was the
first imaging methodology to receive regulatory approval
for the diagnostic evaluation of dementia [10,36]. The
extent and severity of glucose hypometabolism have
been reported to be predictive of conversion to AD in
prodromal AD patients, and to correlate with cognitive
impairment in prodromal and probable AD [11,12,36].
However, for longitudinal use, careful control and
standardization of acquisition are necessary. In fact, as a
measure of brain activity, FDG PET is susceptible to
biological variability due to normal aging, current state
of arousal level, local inflammation, and other non-
neuronal sources of metabolic changes, possibly result-
ing in misdiagnosis [10,13,14].
PET-mediated visualization of the amyloid plaques in
the brain was obtained by using amyloid-β-selective
radioligands, at first with the Pittsburgh compound B
(11C-PiB) and later with the 18 F-labeled tracers (for
example, florbetapir, flutemetamol, and florbetaben)
[16,37]. Since 2011, several of these tracers received
regulatory approval to assist in the diagnosis of dementia
(in particular, for ruling out AD in favor of other forms
of dementia when the amyloid-β signal was absent in
the presence of cognitive impairment, in line with therevised Research Diagnostic Criteria for AD) [1]. How-
ever, since elevated amyloid load was described in up to
15% of non-demented subjects with age-adjusted normal
cognitive profile, it is unclear whether this represents an
early marker for individuals that will develop the disease
soon or normal variations of a biological parameter with
loose association with the disease [35]. More recently,
the abundant NFT pathology, another hallmark of AD,
has been targeted with the initial development of two
novel PET ligands in clinical exploration: 18 F-T-807
and 11C-PBB-3 [38,39]. It is notable that both amyloid-β
peptides and phosphorylated tau levels can be measured
biochemically in the cerebrospinal fluid and are vali-
dated biomarkers in AD research [40], questioning the
need for the more expensive neuroimaging.
Amyloid-β PET recently qualified for the European
regulatory agency (European Medicines Agency, or EMA)
as a biomarker for population enrichment of clinical trials
with prodromal and mild-moderate AD subjects (EMA/
CHMP/SAWP/893622/2011 and EMA/CHMP/SAWP/
892998/2011). Amyloid-β-selective radioligands were also
used to provide evidence of target engagement for NCE
aimed at amyloid-β plaques (that is, bapineuzumab [19]
and gantenerumab [15]). These studies showed a signifi-
cant dose-dependent reduction of the amyloid-β PET
signal over a period of several months of treatment.
However, data available from large clinical trials indicate
that changes of amyloid-β signal were not associated
with changes of disease clinical severity in patients with
AD [19,41] and, to date, should not be used as a surro-
gate marker for efficacy. A final note: the implementa-
tion of PET requires exposure to radioactivity that
limits the repeated use in the same individuals as well as
specialized centers and significant investment. There-
fore, while PET can provide unique and useful informa-
tion, these limitations challenge use in large clinical
trials and even in community-based health care. In fact,
for these reasons, PET is often implemented in a sub-
study of a larger multi-center clinical trial, targeting a
sub-population of the whole study.
Magnetic resonance imaging implementation in
Alzheimer’s disease research
MRI-related techniques are gaining increasing interest
since their use does not require radioactivity exposure
and they can be easily repeated in the same subjects with
no harm, are relatively inexpensive, and can be operated
with scanner machines available in almost any hospital
[6,9,10]. In clinical trials, MRI is commonly used as a
radiologic diagnostic aid to exclude individuals with
incidental brain pathologies. The evidence supporting
their use as specific biomarkers for AD is still limited
(Table 1). We briefly describe the most promising use of
MRI.
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AD, Alzheimer’s disease; APP, amyloid precursor protein; ARIA, amyloid-related imaging abnormality; ASL, arterial spin labeling; BOLD, brain oxygen level-
dependent; CAMD, coalition against major diseases; DTI, diffusion tensor imaging; EMA, European Medicines Agency; FDA, US Food and Drug Administration; FDG,
fluoro-2-deoxy-D-glucose; fMRI, functional magnetic resonance imaging; IV, intravenous; MCI, mild cognitive impairment; MRI, magnetic resonance imaging; PET,
positron emission tomography; SOP, standard operating procedure.
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Structural MRI is an imaging modality that describes the
shape, size, and integrity of gray and white matter struc-
tures in the brain; it is highly sensitive to the atrophic
and vascular changes that occur in the AD central ner-
vous system [6].
Volumetric magnetic resonance imaging
Volumetric MRI is based on data collected by using T1-
weighted sequences that are quantified by using both man-
ual and automatic image analysis. Whereas harmonization
of manually segmented hippocampus is in progress [17],
automated image analysis software (NeuroQuant; Cor-
Techs Labs Inc., San Diego, CA, USA) was recently ap-
proved as a medical device to provide an aid in dementia
diagnosis [18].
Volumetric MRI collected longitudinally at two or
more time points is the most mature imaging biomarker
of disease progression in AD [6], recently supported by
multimodal evidence using FDG [36]. Progression of at-
rophy in the whole brain and in areas targeted by AD
(medial temporal lobe, temporoparietal, and restrosple-
nial cortex) represents a reliable marker of the neurode-
generative process underlying clinical symptoms, more
robust than amyloidosis alone. Hippocampal volumetric
MRI has been validated versus pathologic post-mortem
markers such as neuronal loss and Braak stages [42].
Hippocampal volumetric MRI is qualified by EMA as a
biomarker for enrichment of pre-dementia AD trials
[17], these prodromal subjects having already lost about
20% of its volume. Progression of whole-brain and hip-
pocampal atrophy has been shown to correlate closely
with clinical worsening in patients with AD [6].
Notably, an unexpected paradoxical finding was re-
ported in anti-amyloid immunotherapeutic studies in
AD [19,43], showing a reduced volume in hippocampus,
whole brain, and cortex. These results are calling for a
re-evaluation of the neurobiological interpretation of the
volumetric MRI reduction. The short-term reduction of
brain volume has been hypothesized to result from
changes in fluid balance or amyloid plaque removal ra-
ther than a sustained increase in rate of atrophy. Multi-
modal studies including FDG PET and functional MRI
(fMRI) as well as post-mortem studies would eventually
lead to a better understanding of the biological under-
pinning of this phenomenon.
Methodologically, accurate volumetric assessment re-
quires standard operating procedures that include the
know-how specific for the modality, acquisition parame-
ters, and suitable training of the staff [5]. For this reason,
strict standardization of acquisition and measurement is
being undertaken for manual hippocampal volumetry by
a European Alzheimer’s Disease Consortium (EADC)-
ADNI consortium under the auspices of the Alzheimer’sAssociation [17,44]. The EADC-ADNI standard operat-
ing procedures will be used to validate automated algo-
rithms, such as FreeSurfer and Learning Embeddings
Atlas Propagation. Other brain regions are under active
investigation; for example, the entorhinal cortex showed
performance similar to hippocampus using the Quarc
analysis software (Quarc, Wedemark, Germany) [45].
According to this study, when these markers were used
as primary endpoints, a sample size of about 100 sub-
jects with AD would be sufficient to detect a 25% re-
duction of annual atrophy rate produced by a putative
novel treatment [45]. This is at least threefold less than
the sample size needed when using clinical scales such
as the Alzheimer’s Disease Assessment Scale-cognitive
subscale as endpoints.
Vascular magnetic resonance imaging
The modality of T2-weighted/fluid inversion recovery is
particularly useful to identify vasogenic edema and
microhemorrhages, defined as the amyloid-related im-
aging abnormalities (ARIAs) in AD research [19,43].
Regulatory authorities require their use in clinical trials
implementing the β-amyloid-lowering drugs for safety
reasons. For example, in two bapimezumab phase II
trials, ARIAs occurred in 17% of patients with AD, 78%
of whom did not report clinical correlates [19]. The oc-
currence of ARIAs seems to depend on the dose of the
β-amyloid-lowering drug and on the presence of the
apolipoprotein E4ε genotype, which is characterized by a
significantly higher β-amyloid burden [19,41]. A rating
scale was recently proposed [46].
Diffusion tensor imaging magnetic resonance imaging
Through the assessment of the random motion of water
molecules in the tissue, diffusion tensor imaging (DTI)
has provided new tools to the study of white matter al-
terations in AD brain mostly by assessing two parame-
ters: the fractal anisotropy (FA) and the mean diffusivity
(MD). FA is considered a marker of axonal integrity and
myelinization, whereas MD represents the overall cellu-
lar integrity [47]. The combined use of DTI and volu-
metric MRI in the cingulated cortex was shown to
increase the imaging-based classification of AD cases
versus control with up to 91% accuracy [21]. Initially,
DTI has been perceived as a technique with poor repro-
ducibility and site/scanner dependency. Recent multi-
center trials in Huntington’s disease and AD seem to
contradict this preoccupation, suggesting a low center-
dependent bias and a real possible use as a surrogate
endpoint [22,23].
Functional magnetic resonance imaging
fMRI can be defined as a technology that provides statis-
tical maps of brain activation [6,7]. Brain activation is
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microcirculation produced by local neural activity trig-
gered by external stimuli, behavioral performance, or
neuroactive drugs. Two kinds of magnetic resonance sig-
nals are generally measured: the blood oxygenation
level-dependent (BOLD) and the arterial spin labeling
(ASL) signals [7,48].
Activation task functional magnetic resonance imaging
procedures
Most brain activation maps obtained in patients with
AD have been generated during memory tasks and using
BOLD, showing reduced activity in hippocampus/medial
temporal lobe and increased activity in prefrontal cortex
while encoding new information [30,31]. Similar abnor-
malities, in particular decreases in the medial temporal
lobe, were observed in subjects with prodromal AD/mild
cognitive impairment (MCI) [48]. Intriguingly, increases
were described in the early phase of the disease [32] and
in asymptomatic individuals with genetic risk for AD
[24]. This hyper-activation was interpreted as a possible
compensatory mechanism at work within the networks
whose structures were impaired, a pathologic marker of
impending neural failure [9]. Whereas data on longitu-
dinal test-retest were provided in single-center studies
[33], fMRI activation tasks were very rarely used in
multi-center studies, highlighting the need for further
validation and standardization.
Logistically, the typical fMRI activation task is quite
complex, requiring audio/visual support for stimuli pres-
entation (for example, goggles) and performance record-
ing (for example, joysticks), expert personnel, calibration
procedures for each tasks, and proven invariance to re-
peated exposure (often not studied), therefore making
their implementation difficult in multi-center trials or in
routine use as a diagnostic in the community.
Task-free functional magnetic resonance imaging
procedures
More recently, resting-state fMRI (rs-fMRI) was intro-
duced to collect signals while the subject is not perform-
ing any particular tasks [6,7]. This task-free approach is
ideal in poorly collaborative subjects, such as severely
demented patients, and does not require a specialized
staff. rs-fMRI is based on the collection of time series of
whole-brain MRI signal fluctuations (generally BOLD)
measured in each brain voxel while the subject is at rest
[6,7]. The similarity between time series in different
brain areas can be assessed mathematically as correl-
ation matrices, indicating functional connectivity [29].
Consistent patterns of connectivity at resting state were
reported by several authors, evaluated in test-retest
protocol, and related to specific electrophysiological
signatures in topologically restricted brain areas,exemplified by the ‘default mode’ network (DMN) [34].
In AD, impaired DMN has been reported, including lon-
gitudinal data that showed a correlation with clinical
symptom worsening [6]. Interestingly, rs-fMRI studies in
non-demented adults carrying a familial AD gene muta-
tion showed hyper-connectivity in the dorsolateral
prefrontal cortex and decreased connectivity in the pre-
cuneus [26,27]. rs-fMRI is also a stronger classifier than
memory task-associated fMRI when used in non-
demented adults carrying a familial AD mutation [27].
Interestingly, changes of connectivity in the DMN of
subjects with AD were observed following chronic treat-
ment with memantine [49] and donepezil [25].Arterial spin labeling
In the last few years, ASL has attracted the attention of
various research groups [7]. ASL MRI was validated ver-
sus perfusion PET showing convergent information
about regional cerebral blood flow of diagnostic rele-
vance, with higher resolution and no exposure to radio-
active tracers [25,28]. Evidence of hypoperfusion in AD
and prodromal AD/MCI conditions was confirmed and
extended to a series of other brain areas, and the initial
evidence is that ASL may have properties of diagnostics
and markers of disease severity [20,25,50]. ASL measure-
ments appear less variable than BOLD in test-retest tri-
als in a single center. Unfortunately, to date, it cannot be
easily implemented in multi-center trials since different
vendors of MRI scanners have implemented different se-
quences of acquisition, therefore hindering comparison
among sites with different MRI scanners.Conclusions and future directions
There is a role for MRI as a biomarker in clinical trials
aimed at the development of new treatment for AD.
However, a series of challenges is still looming, in par-
ticular for fMRI. Among them, we have identified reli-
ability and repeatability for specific tests, standardization
across multiple sites, development of validated auto-
mated quantification tools, implementation of multiple
modalities (for example, merging PET and rs-fMRI), cost
optimization, and selection of the most accurate and ef-
ficient diagnostic combination of markers, including
fluid-based biomarker modalities. Most of these chal-
lenges are tackled in the context of large consortia in-
volving collaborations between academia and industry as
well as in some contract research organizations and
technology-oriented academic centers. The delivery of
this research is of relevance for building confidence in
imaging biomarkers: at present, with the exception of
safety assessment of ARIA signals, the implementation
of MRI in pharmaceutical clinical trials is still seen as
exploratory rather than decision-making.
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